In particular, Trametinib-treated cancer cells showed de novo enhancer formation near the DDR1 gene that were enriched for BRD4 (bromodomain-containing protein 4) binding, which promoted a drastic increase in DDR1 expression. Here, BRD4 is linked to cancer.